Exhibit 10.1


 


CONFIDENTIAL


EXECUTION VERSION





 


SECURITIES
PURCHASE AGREEMENT


 


This
Securities Purchase Agreement (this “Agreement”) is dated as of January 3, 2017, between China Jo-Jo Drugstores,
Inc., a Nevada corporation (the “Company”), and CareRetail Holdings Limited, an exempt company incorporated
under the laws of the Cayman Islands (the “Purchaser” ).


 


WHEREAS,
subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to the Purchaser, and the
Purchaser desires to purchase from the Company, securities of the Company as more fully described in this Agreement.


 


NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Company and the Purchaser agree as follows:


 


ARTICLE
I



DEFINITIONS


 


Section
1.1 Definitions. In addition to the terms defined elsewhere
in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:


 


“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.5.


 


“Action”
shall have the meaning ascribed to such term in Section 3.1(j).


 


“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.


 


“Board
of Directors” means the board of directors of the Company.


 


“Business
Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or
any day on which banking institutions in the State of New York are authorized or required by law or other governmental action
to close.


 


“Closing”
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.


 


“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchaser’s obligations to pay the Subscription Amount and (ii)
the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later
than the 20th Trading Day following the date hereof, unless the parties agree in writing to extend the Closing Date.


 


“Commission”
means the United States Securities and Exchange Commission.


 



     


     


    

 





CONFIDENTIAL


EXECUTION VERSION




 


“Common
Stock” means the common stock of the Company, par value US$0.001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.


 


“Common
Stock Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.


 


“Company
Nevada Counsel” means Holley Driggs Walch Fine Wray, a law firm based in the State of Nevada with attorneys licensed
in the State of Nevada.


 


“Company
N.Y. Counsel” means Pryor Cashman LLP, with offices located at 7 Times Square, New York, New York 10036.


 


“Evaluation
Date” shall have the meaning ascribed to such term in Section 3.1(s).


 


“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.


 


“Existing
Preemptive Right” means the preemptive right granted to each of Sabby Volatility Warrant Master Fund, Ltd. and Sabby
Healthcare Master Fund, Ltd. pursuant to Section 4.11 of the Securities Purchase Agreement dated as of July 19, 2015 entered into
by and among the Company, Sabby Volatility Warrant Master Fund, Ltd. and Sabby Healthcare Master Fund, Ltd.


 


“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.


 


“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).


 


“Governmental
Authority” means any international, domestic or foreign federal, state or local governmental, regulatory or administrative
authority, department, court, agency or official, including any political subdivision thereof.


 


“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(aa).


 


“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(p).


 


“Investor
Rights Agreement” means the investor rights agreement entered into by and among (i) the Company, (ii) Hangzhou Jiuzhou
Grand Pharmacy Chain Co., Ltd. (杭州九洲大药房连锁有限公司),
(iii) Lei Liu, (iv) Li Qi, (v) Super Marvel Limited and (vi) the Purchaser, on the date hereof.


 


“Joint
Venture Agreements” means, collectively, the agreements substantially in the forms of Exhibit A-1 and Exhibit A-2 attached
hereto.


 



    	 	2	 



     


    

 





CONFIDENTIAL


EXECUTION VERSION


 


“knowledge”
of any Person that is not an individual means the knowledge of such Person’s directors and officers, and the knowledge that
each such person would have reasonably obtained after making due and appropriate inquiry.


 


“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.


 


“Material
Adverse Effect” shall have the meaning assigned to such term in Section 3.1(b).


 


“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(n).


 


“Onshore
Restructuring” means the transfer of all operations and assets of Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (杭州九洲大药房连锁有限公司),
a variable interest entity controlled by the Company, to the Company and/or its designated wholly-owned Subsidiaries, subject
to and conditional upon such terms as agreed to by the Company and the Purchaser.


 


“Per
Share Purchase Price” equals US$2.20, subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.


 


“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.


 


“Preferred
Stock” means the preferred stock of the Company, par value US$0.001 per share, and any other class of securities into
which such securities may hereafter be reclassified or changed.


 


“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or threatened.


 


“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.8.


 


“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).


 


“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.


 


“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h). “Securities” means the Shares.


 


“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 



    	 	3	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


“Shares”
means the shares of Common Stock issued or issuable to the Purchaser pursuant to this Agreement.


 


“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall
not be deemed to include the location and/or reservation of borrowable shares of Common Stock).


 


“Subscription
Amount” means, as to the Purchaser, the aggregate amount to be paid for Shares purchased hereunder as specified below
the Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,”
in United States dollars and in immediately available funds.


 


“Subsidiary”
means, with respect to the Company, any entity of which a majority of the outstanding equity securities or other ownership interests
representing a majority of the outstanding equity interests or otherwise having voting power to elect a majority of the board
of directors or other Persons performing similar functions are at the time directly or indirectly owned by the Company. For the
avoidance of doubt, the Subsidiaries of the Company shall include any variable interest entity over which the Company or any of
its Subsidiaries effects control pursuant to contractual arrangements and which is consolidated with the Company in accordance
with generally accepted accounting principles applicable to the Company.


 


“Trading
Day” means a day on which the principal Trading Market is open for trading.


 


“Trading
Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the
New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).


 


“Transaction
Documents” means this Agreement, the Investor Rights Agreement, the Joint Venture Agreements, and any other documents
or agreements executed in connection with the transactions contemplated hereunder.


 


“Transfer
Agent” means American Stock Transfer & Trust Company, LLC, the current transfer agent of the Company, and any successor
transfer agent of the Company.


 


ARTICLE
II



PURCHASE AND SALE


 


Section
2.1 Closing. On the Closing Date, upon the terms and
subject to the conditions set forth herein, the Company agrees to issue and sell to the Purchaser, and the Purchaser agrees to
purchase, an aggregate of US$10,648,000 of Common Stock, with a per Common Stock purchase price equal to the Per Share Purchase
Price. The Purchaser shall deliver to the Company, via wire transfer, immediately available funds equal to the Purchaser’s
Subscription Amount as set forth on the signature page hereto executed by the Purchaser, and the Company shall deliver to the
Purchaser its Shares pursuant to Section 2.2(a), and the Company and the Purchaser shall deliver the other items set forth in
Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the
Closing shall occur remotely via exchange of documents and signatures.


 



    	 	4	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
2.2 Deliveries.


 


(a)
On or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the
following:


 


(i)
this Agreement duly executed by the Company;


 


(ii)
a legal opinion letter of Company N.Y. Counsel and a legal opinion letter of Company Nevada Counsel, in each case addressed to
the Purchaser and in such form that is satisfactory to the Purchaser;


 


(iii)
a notarized true copy of the complete stockholder ledger of the stockholders of the Company as of the Closing Date, reflecting
the issuance of the Shares to, and the ownership of the Shares by, the Purchaser;


 


(iv) an original stock certificate representing the Shares duly executed on behalf of the Company and registered in the name of the
Purchaser;


 


(v)
certified true copies of the resolutions of the Board of Directors and any other required corporate approvals of the Company
duly authorizing and approving this Agreement and the other Transaction Documents and the transactions contemplated hereunder
and thereunder;


 


(vi)
certified true copies of all approvals, consents and waivers necessary for the consummation of the transactions contemplated
hereby or by any other Transaction Document, including without limitation all consents and waivers, each in such form that is
reasonably satisfactory to the Purchaser, of all stockholders of the Company having preemptive rights consenting to the
transactions contemplated hereby and by any other Transaction Document and fully waiving the preemptive rights of such
stockholders with respect to the issuance and sale of the Shares, as well as authorizations, approvals or permits, if any, of
any Governmental Authority; and


 


(vii)
a copy of each of the Joint Venture Agreements, duly executed and delivered by the Subsidiaries that is a party
thereto.


 


(b)
On or prior to the Closing Date, the Purchaser shall deliver or cause to be delivered to the Company the
following:


 


(i)
this Agreement duly executed by the Purchaser; and


 


(ii)
the Purchaser’s Subscription Amount by wire transfer to the bank account of the Company, which account information the Company
shall have provided to the Purchaser no later than five (5) Business Days prior to the Closing Date.


 



    	 	5	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
2.3 Closing Conditions.


 


(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met,
any or all of which may be waived in whole or in part by the Company to the extent permitted by applicable law:


 


(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) on the Closing Date of the representations and warranties of the Purchaser contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);


 


(ii)
all obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have
been performed; and


 


(iii) 
the delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.


 


(b)
The obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met,
any or all of which may be waived in whole or in part by the Purchaser to the extent permitted by applicable law:


 


(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material
Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained
herein (unless as of a specific date therein in which case they shall be accurate as of such date);


 


(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been
performed;


 


(iii) 
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;


 


(iv) 
there shall have been no Material Adverse Effect with respect to the Company or any Subsidiary since the date hereof;


 


(v)
the Company shall have obtained any and all approvals, consents and waivers necessary for the consummation of the transactions
contemplated hereby or by any other Transaction Document, including without limitation all consents and waivers, each in such
form that is reasonably satisfactory to the Purchaser, of all stockholders of the Company having preemptive rights consenting
to the transactions contemplated hereby and by any other Transaction Document and fully waiving the preemptive rights of such
stockholders with respect to the issuance and sale of the Shares, as well as all authorizations, approvals or permits, if any,
of any Governmental Authority;


 


(vi) 
the parties to the Joint Venture Agreements shall have obtained any and all approvals, consents and waivers necessary for the
consummation of the transactions contemplated by the Joint Venture Agreements or have provided evidence of the submission of all
requisite materials to the Governmental Authority for the purpose of obtaining its authorizations, approvals or permits, if any,
of such Governmental Authority; and


 



    	 	6	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(vii)
from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg
L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are
reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States
or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in
each case, in the reasonable judgment of the Purchaser, makes it impracticable or inadvisable to purchase the Securities at the
Closing.


 


ARTICLE
III



REPRESENTATIONS AND WARRANTIES


 


Section
3.1 Representations and Warranties of the Company. The
Company hereby makes the following representations and warranties to the Purchaser:


 


(a) Subsidiaries.
All of the Subsidiaries are set forth on Schedule A hereto. The Company owns, directly or indirectly, all of the capital
stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares
of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar
rights to subscribe for or purchase securities.


 


(b)  Organization
and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise
organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization,
with the requisite power and authority to own and use its properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective
certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company and the
Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each
jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to
result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a
material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of
the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to
perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii),
a “Material Adverse Effect”) and no Proceeding has been instituted in any such jurisdiction revoking,
limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.


 



    	 	7	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(c) 
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company
and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action
on the part of the Company and no further action is required by the Company, the Board of Directors or the Company’s stockholders
in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii)
as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)
insofar as indemnification and contribution provisions may be limited by applicable law.


 


(d)
No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents
to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby
and thereby do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default
(or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon
any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which
any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including, without limitation, federal and state securities
laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case
of each of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.


 


(e) 
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of,
give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority
or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other
than: (i) the filing of certain current reports on Form 8-K with the Commission in respect of the transactions contemplated hereunder
and (ii) application(s) to each applicable Trading Market for the listing of the Shares for trading thereon in the time and manner
required thereby (the items listed in clauses (i) and (ii) above collectively, the “Required Approvals”) and
(iii) such consents and waivers of the stockholders of the Company regarding the Existing Preemptive Rights.


 



    	 	8	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(f) 
Issuance of the Securities; No Registration. The Securities are duly authorized and, when issued and paid for in accordance
with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of
all Liens. The Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable
pursuant to this Agreement. It is not necessary in connection with the issuance and sale of the Shares to register the Shares
under the Securities Act or to qualify or register the Shares under applicable U.S. state securities laws. None of the Company,
its Subsidiaries or their respective Affiliates or any Person acting on its or their behalf have engaged in any “directed
selling efforts” within the meaning of Rule 903 of Regulation S under the Securities Act (“Regulation S”)
or any form of general solicitation or general advertising within the meaning of Rule 502(c) under the Securities Act with
respect to the Shares.


 


(g)
Capitalization. The capitalization of the Company is as set forth on Schedule B hereto. The Company has not issued any
capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee
stock options under the Company’s stock option plans, the issuance of shares of Common Stock to employees pursuant to the
Company’s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the Exchange Act. Except for the Existing Preemptive Right, no
Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except as a result of the purchase and sale of the Securities, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities,
rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or
acquire, any shares of Common Stock, Preferred Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings
or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock, Preferred
Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock, Preferred Stock or other securities to any Person (other than the
Purchaser) and will not result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or
reset price under any of such securities. There are no outstanding securities or instruments of the Company or any Subsidiary
that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by
which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company
does not have any stock appreciation rights or “phantom stock” plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable,
have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any
stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders
agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among any of the Company’s stockholders.


 



    	 	9	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION







 


(h)
SEC Reports; Financial Statements. The Company has filed or furnished, as applicable, all reports, schedules, forms, statements
and other documents required to be filed or furnished by the Company under the Securities Act and the Exchange Act, including,
without limitation, pursuant to Section 13(a) or 15(d) thereof, (all of the foregoing materials filed with or furnished to the
Commission, including all exhibits thereto, financial statements, notes and schedules thereto and documents incorporated by reference
therein, being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid
extension of such time of filing or furnishing and has filed or furnished, as applicable, any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of
the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed or furnished, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of
the Company included or incorporated by reference in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial
statements (including without limitation any related notes thereto) have been prepared in accordance with United States generally
accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”), except as
may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may
not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company
and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods
then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.


 


(i)
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements
included or incorporated by reference the SEC Reports, except as specifically disclosed in a subsequent SEC Report filed prior
to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to
result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A)
trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the
Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem
any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate,
except pursuant to existing Company stock option plans. The Company does not have pending before the Commission any request for
confidential treatment of information. Except for the issuance of the Securities contemplated by this Agreement, no event, liability,
fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect
to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least three Trading Days prior to the date that this representation is
made.


 



    	 	10	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(j)
Litigation. Other than as disclosed in the SEC Reports, there is no material action, suit, inquiry, notice of violation,
proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory
authority (federal, state, county, local or foreign) (collectively, an “Action”). Neither the Company nor any
Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge
of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current
or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness
of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.


 


(k)
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company
and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract,
confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement
or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not
subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and
its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment
and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance
could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.


 


(l)
Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation
of, any material indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it
or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment,
decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute,
rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local
laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and
labor matters, except in each case as disclosed in the SEC Reports or immaterial defaults or violations.


 



    	 	11	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(m) 
Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws
relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land
surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals,
pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”)
into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport
or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(“Environmental Laws”); (ii) have received all permits licenses or other approvals required of them under applicable
Environmental Laws tic induct their respective businesses; and (iii) are in compliance with all terms and conditions of any such
permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to
have, individually or in the aggregate, a Material Adverse Effect.


 


(n)
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the
appropriate federal, state, local or foreign regulatory authorities necessary and material to conduct their respective businesses
as described in the SEC Reports, except as disclosed in the SEC Reports (“Material Permits”), and neither the
Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.


 


(o)
Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned
by them and good and marketable title in all personal property owned by them that is material to the business of the Company and
the Subsidiaries, in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries
and (ii) Liens for the payment of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance
with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under
lease by the Company and the Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company
and the Subsidiaries are in compliance.


 


(p)
Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications,
trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in
the SEC Reports, except as disclosed in the SEC Reports or where the failure to do so could not reasonably be expected to result
in a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None of, and neither the Company
nor any Subsidiary has received a notice (written or otherwise) that any of the Intellectual Property Rights has expired, terminated
or been abandoned, or is expected to expire or terminate or be abandoned, within three (3) years from the date of this Agreement.
Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within
the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the
knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another
Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to
protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.


 



    	 	12	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(q)
Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such
losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries
are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription
Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue
its business without a significant increase in cost.


 


(r)
Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of
the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is
presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors),
including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental
of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring
payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner,
in each case in excess of US$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement
for expenses incurred on behalf of the Company and (iii) equity grants under any stock option plan of the Company.


 


(s) 
Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in compliance with any and all applicable
requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and
regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that:
(i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the
recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and
procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms.
The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such
date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial
reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or
is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.


 



    	 	13	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(t)
Certain Fees. No brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary
to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect
to the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation with respect to any fees
or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be
due in connection with the transactions contemplated by the Transaction Documents.


 


(u)
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended. The Company shall conduct its business in a manner so that it will not become an “investment company”
subject to registration under the Investment Company Act of 1940, as amended.


 


(v)
Registration Rights. Other than the Purchaser, no Person has any right to cause the Company or any Subsidiary to effect
the registration under the Securities Act of any securities of the Company or any Subsidiary.


 


(w) 
Listing and Maintenance Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange
Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating
terminating such registration. The Company has not received notice from any Trading Market on which the Common Stock is or has
been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such
Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance
with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the
Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the
Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.


 


(x)
Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in
order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation (or similar
charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchaser as a result of
the Purchaser and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including
without limitation as a result of the Company’s issuance of the Securities and the Purchaser’s ownership of the Securities.


 



    	 	14	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(y)
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Purchaser or its agents
or counsel with any information that it believes constitutes or might constitute material, non-public information. The Company
understands and confirms that the Purchaser will rely on the foregoing representation in effecting transactions in securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser regarding the Company and its
Subsidiaries, their respective businesses and the transactions contemplated hereby, is true and correct and does not contain any
untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company preceding
the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.


 


(z) 
No Integrated Offering. Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section
3.2, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would (i) cause
this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder
approval provisions of any Trading Market on which any of the securities of the Company are listed or designated or (ii) require
registration of the issuance of any of the Shares under the Securities Act, whether through integration with prior offerings or
otherwise.


 


(aa)
Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the
receipt by the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company’s
assets exceeds the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities
(including known contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small
capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account
the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. Schedule C hereto sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money or amounts owed in excess of US$50,000 (other than trade accounts payable incurred
in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business; and (z) the present value of any lease payments in excess of US$50,000 due under leases required
to be capitalized in accordance with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.


 






    	 	15	 



     


    

  


CONFIDENTIAL


EXECUTION VERSION


 







(bb)
Tax Status. Except as disclosed in the SEC Reports, or for matter(s) that are not, individually or in the aggregate, material,
the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign
income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid
all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such returns,
reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes
for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know
of no basis for any such claim.


 


(cc)
Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary,
any agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for
unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii)
made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties
or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made
by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material
respect any provision of FCPA.


 


(dd) 
Accountants. The Company’s accounting firm is set forth on Schedule D hereto. To the knowledge and belief of the
Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express
its opinion with respect to the financial statements to be included in the Company’s Annual Report for the fiscal year ending
March 31, 2017.


 


(ee)
Acknowledgment Regarding Purchaser’s Purchase of Securities. The Company acknowledges and agrees that the Purchaser
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary of
the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and
any advice given by the Purchaser or any of its representatives or agents in connection with the Transaction Documents and the
transactions contemplated thereby is merely incidental to the Purchaser’s purchase of the Securities. The Company further
represents to the Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.


 



    	 	16	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(ff) 
Acknowledgement Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary
notwithstanding, it is understood and acknowledged by the Company that: (i) the Purchaser has not been asked by the Company to
agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or “derivative”
securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open
market or other transactions by the Purchaser, specifically including, without limitation, Short Sales or “derivative”
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price
of the Company’s publicly-traded securities; (iii) the Purchaser, and counter-parties in “derivative” transactions
to which the Purchaser is a party, directly or indirectly, presently may have a “short” position in the Common Stock,
and (iv) the Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in
any “derivative” transaction. The Company further understands and acknowledges that (y) the Purchaser may engage in
hedging activities at various times during the period that the Securities are outstanding, and (z) such hedging activities (if
any) could reduce the value of the existing stockholders’ equity interests in the Company at and after the time that the
hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do not constitute
a breach of any of the Transaction Documents.


 


(gg)
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting
another to purchase any other securities of the Company.


 


(hh)
Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).


 


(ii)
U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s
request.


 


(jj)
Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding
Company Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve
System (the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls,
directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent
or more of the total equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither
the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve.


 



    	 	17	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(kk) Money
Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in
compliance with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder
(collectively, the “Money Laundering Laws”), and no Action or Proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money
Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.


 


Section
3.2 Representations and Warranties of the Purchaser.
The Purchaser hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless
as of a specific date therein):


 


(a) Organization;
Authority. The Purchaser is an entity duly incorporated or formed, validly existing and in good standing under the laws
of the jurisdiction of its formation with full right, corporate, partnership, limited liability company or similar power and
authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its
obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by the Purchaser of
the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited
liability company or similar action, as applicable, on the part of the Purchaser. Each Transaction Document to which it is a
party has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will
constitute the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms,
except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and
other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as
indemnification and contribution provisions may be limited by applicable law.


 


(b) Understandings
or Arrangements. The Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting the Purchaser’s right to sell the Securities in compliance with
applicable federal and state securities laws).


 


(c) Experience
of the Purchaser. The Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the
prospective investment in the Securities and has so evaluated the merits and risks of such investment. Such Purchaser is able
to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of
such investment.


 


(d) 
Regulation S Compliance.


 


(i)
The Purchaser is not a U.S. Person as such term is defined under Rule 902 of Regulation S (“U.S. Person”). The Purchaser
is at the time of the offer and execution of this Agreement, domiciled outside the United States.


 


(ii)
The Purchaser agrees that all offers and sales of the Shares from the date hereof and through the expiration of any restricted
period set forth in Rule 903 of Regulation S (as the same may be amended from time to time hereafter) shall not be made to U.S.
Persons or for the account or benefit of U.S. Persons and shall otherwise be made in compliance with the provisions of Regulation
S and any other applicable provisions of the Securities Act.


 



    	 	18	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


(iii) 
The Purchaser shall not engage in hedging transactions with regard to the Shares unless in compliance with the Securities Act.
This Agreement and the transactions contemplated herein are not part of a plan or scheme to evade the registration provisions
of the Securities Act, and the Shares are being acquired for investment purposes by the Purchaser.


 


(iv) 
The Purchaser acknowledges that the Company will refuse to register any transfer of any of the Shares not made in accordance with
the provisions of Regulation S, pursuant to an effective registration statement under the Securities Act or pursuant to an available
exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.


 


(v)
Purchaser acknowledges and agrees that the certificate(s) representing the Shares will bear a legend substantially as follows:


 


THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), AND ARE RESTRICTED SECURITIES AS THAT TERM IS DEFINED IN RULE 144 UNDER THE SECURITIES ACT. THE SHARES HAVE BEEN
ISSUED IN AN OFFSHORE TRANSACTION BY CHINA JO-JO DRUGSTORES, INC., IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT PROVIDED BY REGULATION S. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD OR OTHERWISE TRANSFERRED, EITHER
DIRECTLY OR INDIRECTLY, IN THE UNITED STATES (AS DEFINED IN REGULATION S) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH REGULATION
S, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER
THE SECURITIES ACT, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE REASONABLE SATISFACTION OF CHINA JO-JO DRUGSTORES, INC.
HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.


 


(e) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, the
Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or
indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period
commencing as of the time that the Purchaser first received a term sheet (written or oral) from the Company or any other
Person representing the Company setting forth the material pricing terms of the transactions contemplated hereunder and
ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of the Purchaser that is a
multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser’s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of the Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of
assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement. Other than to other Persons party to this Agreement or to the Purchaser’s representatives, including,
without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, the
Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the
existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein
shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the
availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the
future.


 



    	 	19	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect the Purchaser’s
right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this
Agreement or the consummation of the transaction contemplated hereby.


 


ARTICLE
IV



OTHER AGREEMENTS OF THE PARTIES


 


Section
4.1 Further Assurances; Joint Venture. The Company and
the Purchaser shall use their reasonable best efforts to take all actions necessary or advisable and do all things (including
to execute and deliver documents and other papers) necessary or advisable to promptly consummate the transactions contemplated
by this Agreement and the other Transaction Documents, including without limitation the formation of the joint venture pursuant
to the terms of the Joint Venture Agreements. The Company covenants to the Purchaser that the Company shall, at its own cost,
promptly (i) obtain all Required Approvals and (ii) procure the completion of the Onshore Restructuring in no event later than
the first anniversary of the Closing Date.


 


Section
4.2 Furnishing of Information. Until the time that the
Purchaser owns no Securities, the Company covenants to timely file (or obtain extensions in respect thereof and file within the
applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even
if the Company is not then subject to the reporting requirements of the Exchange Act.


 


Section
4.3 Integration. The Company shall not, and shall cause
its Affiliates and any Person acting on its or their behalf not to, directly or indirectly, sell, offer for sale or solicit offers
to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would (i) be integrated
with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require
shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing
of such subsequent transaction or (ii) require registration of the issuance of any of the Shares under the Securities Act whether
through integration with prior offerings or otherwise.


 



    	 	20	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
4.4 Securities Laws Disclosure; Publicity. Each party
hereto agrees to consult with the other parties hereto before issuing or making, and to provide each other reasonable prior opportunity
to review, comment upon and concur with, and use all reasonable efforts to agree on, any press release, public statement or disclosure
with respect to this Agreement or the other Transaction Documents or the transactions contemplated hereby or thereby. Notwithstanding
anything herein to the contrary, the Company agrees not to issue any such press release, public statement or disclosure in respect
of the Purchaser or its Affiliates without the prior written consent of the Purchaser.


 


Section
4.5 Shareholder Rights Plan. No claim will be made or
enforced by the Company or, with the consent of the Company, any other Person, that the Purchaser is an “Acquiring Person”
under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or
similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that the Purchaser could be deemed
to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or
under any other agreement between the Company and the Purchaser.


 


Section
4.6 Non-Public Information. Except with respect to the
material terms and conditions of the transactions contemplated by the Transaction Documents, the Company covenants and agrees
that neither it, nor any other Person acting on its behalf will provide the Purchaser or its agents or counsel with any information
that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto the Purchaser
shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The
Company understands and confirms that the Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. To the extent that the Company delivers any material, non-public information to the Purchaser without the Purchaser’s
consent, the Company hereby covenants and agrees that the Purchaser shall not have any duty of confidentiality to the Company,
any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company,
any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis
of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. The Company understands
and confirms that the Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.


 


Section
4.7 Use of Proceeds. The Company shall use the net proceeds
from the sale of the Securities hereunder only for working capital and general corporate purposes, and shall not use such proceeds:
(a) for the satisfaction of any portion of the Company’s debt (other than payment of trade payables in the ordinary course
of the Company’s business and prior practices), (b) for the redemption of any Common Stock, Preferred Stock or Common Stock
Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.


 



    	 	21	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
4.8 Indemnification of Purchaser. Subject to the provisions
of this Section 4.8, the Company will indemnify and hold the Purchaser and its directors, officers, shareholders, members, partners,
employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title), each Person who controls the Purchaser (within the meaning of Section 15 of the Securities
Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and
any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or
any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur
as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity,
or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party,
with respect to any of the transactions contemplated by the Transaction Documents (unless such action is based upon a breach of
such Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities
laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence, willful misconduct or malfeasance). If
any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement,
such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense
thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right
to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel
shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized
by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between
the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable
fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this
Agreement (y) for any settlement by a Purchaser Party effected without the Company’s prior written consent, which shall
not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability
is directly attributable to any Purchaser Party’s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section
4.8 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills
are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar
right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law or
equity.


 


Section
4.9 Reservation of Common Stock. As of the date hereof,
the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights,
a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement.


 



    	 	22	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
4.10   Listing of Common Stock. The Company hereby agrees to take all actions necessary
and to use best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently
listed, and concurrently with the execution of this Agreement, the Company shall, at its own cost, apply to list or quote all
of the Shares on such Trading Market and promptly secure the listing of all of the Shares on such Trading Market, no later than
such date as reasonably requested by the Purchaser. The Company further agrees, if the Company applies to have the Common Stock
traded on any other Trading Market, it will then include in such application all of the Shares, and will take such other action
as is necessary to cause all of the Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company
will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and
will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the
Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository
Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository
Trust Company or such other established clearing corporation in connection with such electronic transfer.


 


Section
4.11   Capital Changes. Until the one year anniversary of the Closing Date, the
Company shall not undertake a reverse or forward stock split or reclassification of the Common Stock without the prior written
consent of the Purchaser except for the purposes of maintaining its compliance with Section 4.10 herein.


 


Section
4.12   Notification of Certain Matters. From and after the date of this Agreement
until the earlier to occur of the Closing Date or termination of this Agreement in accordance with its terms, the Company shall
give prompt notice to the Purchaser of (i) the discovery of any fact or circumstance, or the occurrence, or non-occurrence, of
any event which would reasonably be expected to cause any condition to the obligation of any party to effect the transactions
contemplated hereunder or by the other Transaction Documents not to be satisfied or the satisfaction of those conditions being
materially delayed, and (ii) any failure of the Company to comply with or satisfy any covenant, condition or agreement to be complied
with or satisfied by it under this Agreement or the other Transaction Documents which would reasonably be expected to cause any
condition to the obligation of any party to effect the transactions contemplated hereunder or thereunder not to be satisfied or
the satisfaction of those conditions being materially delayed. From and after the date of this Agreement until the earlier to
occur of the Closing Date or termination of this Agreement in accordance with its terms, the Company shall give prompt notice
to the Purchaser of any written notice or other written communication from any Governmental Authority in connection with the transactions
contemplated hereunder or by the other Transaction Documents.


 


ARTICLE
V



MISCELLANEOUS


 


Section
5.1 Termination. In the event that the Closing shall
not have occurred within twenty (20) Trading Days after the date hereof, then this Agreement may be terminated by the Purchaser;
provided, however, that (a) the right to terminate this Agreement under this Section 5.1 shall not be available
to the Purchaser if the failure of the transactions contemplated by this Agreement to have been consummated by the Closing Date
is the result of the Purchaser’s failure to fulfill any condition or requirement set forth in this Agreement; and (b) no
such termination will affect the right of any party to sue for any breach by any other party (or parties).


 



    	 	23	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
5.2 Fees and Expenses. Except as expressly set forth
in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants
and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution,
delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any
fees required for processing of any instruction letter delivered by the Company), stamp taxes and other taxes and duties levied
in connection with the delivery of any Securities to the Purchaser.


 


Section
5.3 Entire Agreement. The Transaction Documents, together
with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof
and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties
acknowledge have been merged into such documents, exhibits and schedules.


 


Section
5.4 Notices. Any and all notices or other communications
or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the
earliest of: (a) the date of transmission, if such notice or communication is delivered via facsimile or e-mail attachment at
the facsimile number or email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City
time) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered
via facsimile or email attachment at the facsimile number or email address as set forth on the signature pages attached hereto
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd)
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual
receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as
set forth on the signature pages attached hereto.


 


Section
5.5 Amendments; Waivers. No provision of this Agreement
may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company
and the Purchaser or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No
waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof,
nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any amendment effected in accordance with this Section 5.5 shall be binding upon the Purchaser and holder of Securities and the
Company.


 


Section
5.6 Headings. The headings herein are for convenience
only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.


 


Section
5.7 Successors and Assigns. This Agreement shall be binding
upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this Agreement
or any rights or obligations hereunder without the prior written consent of the Purchaser (other than by merger). The Purchaser
may assign any or all of its rights under this Agreement to any Person to whom the Purchaser assigns or transfers any Securities,
provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of
the Transaction Documents that apply to the “Purchaser.”


 



    	 	24	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
5.8 No Third-Party Beneficiaries. This Agreement is intended
for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor
may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.


 


Section
5.9 Governing Law; Dispute Resolution. All questions
concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed and
enforced in accordance with the internal laws of the State of New York. Any dispute, controversy or claim arising out of or relating
to this Agreement, including, but not limited to, any question regarding the breach, termination or invalidity thereof shall be
finally resolved by arbitration in Hong Kong in accordance with the administered rules (the “Rules”) of the
Hong Kong International Arbitration Centre (the “HKIAC”) in force at the time of commencement of the arbitration,
which Rules are deemed to be incorporated by reference into this Section. The number of arbitrators shall be three and shall be
selected in accordance with the Rules. All selections shall be made within thirty (30) days after the selecting party gives or
receives, as the case may be, the demand for arbitration. The seat of the arbitration shall be in Hong Kong and the language to
be used shall be English. Any arbitration award shall be (i) in writing and shall contain the reasons for the decision, (ii) final
and binding on the parties hereto and (iii) enforceable in any court of competent jurisdiction, and the parties hereto agree to
be bound thereby and to act accordingly.


 


Section
5.10   Survival. The representations and warranties contained herein shall survive
the Closing and the delivery of the Securities.


 


Section
5.11   Execution. This Agreement may be executed in two or more counterparts, all
of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have
been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.
In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf’ format data
file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is
executed) with the same force and effect as if such facsimile or “.pdf’ signature page were an original thereof.


 


Section
5.12   Severability. If any term, provision, covenant or restriction of this Agreement
is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions,
covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or
invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to
achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is
hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions,
covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.


 


Section
5.13   Rescission and Withdrawal Right. Notwithstanding anything to the contrary
contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever the Purchaser exercises
a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations
within the periods therein provided, then the Purchaser may rescind or withdraw, in its sole discretion from time to time upon
written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions
and rights.


 



    	 	25	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION


 


Section
5.14   Replacement of Securities. If any certificate or instrument evidencing any
Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution
for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for
a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary
indemnity) associated with the issuance of such replacement Securities.


 


Section
5.15   Remedies. In addition to being entitled to exercise all rights provided
herein or granted by law, including recovery of damages, the Purchaser and the Company will be entitled to specific performance
under this Agreement. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason
of any breach of obligations contained in this Agreement and hereby agree to waive and not to assert in any Action for specific
performance of any such obligation the defense that a remedy at law would be adequate.


 


Section
5.16   Payment Set Aside. To the extent that the Company makes a payment or payments
to the Purchaser pursuant to any Transaction Document or the Purchaser enforces or exercises its rights thereunder, and such payment
or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent
or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company,
a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law,
common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred.


 


Section
5.17   Liquidated Damages. The Company’s obligations to pay any partial liquidated
damages or other amounts owing under the Transaction Documents is a continuing obligation of the Company and shall not terminate
until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security
pursuant to which such partial liquidated damages or other amounts are due and payable shall have been canceled.


 


Section
5.18   Saturdays, Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may
be taken or such right may be exercised on the next succeeding Business Day.


 


Section
5.19   Construction. The parties agree that each of them and/or their respective
counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction
to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of
the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and shares of Common
Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock
combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.


 


(Signature
Pages Follow)


 






    	 	26	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.


 


	CHINA
    JO-JO DRUGSTORES, INC.	 	Address
    for Notice:
	 	 	 	 
	By:	/s/
    Lei Liu	 	Hangzhou
    Jiuzhou Grand Pharmacy Chain Co., Ltd.
	 	Name:
    Lei Liu	 	(杭州九洲大药房连锁有限公司)
	 	Title:
    Chief Executive Officer	 	 1st
Floor, Yuzheng Plaza, No. 76,

	 	 	 	Yuhuangshan
    Road, Hangzhou, 

Zhejiang Province, Zip Code: 310002
	 	 	 	People’s
Republic of China

Attention: Lei Liu, c/o: Ming Zhao

	 	 	 	Facsimile:
        0571-88219579

        E-mail:hz.liulei@163.com;
        

frank.zhao@jojodrugstores.com



 


With
a copy to (which shall not constitute notice):


 


Pryor
Cashman LLP

7 Times Square, New York, NY 10036

Attention: Elizabeth Fei Chen, Esq.

Facsimile: 212-798-6366

E-mail: echen@pryorcashman.com


 


[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK; SIGNATURE PAGE FOR PURCHASER FOLLOWS]


 






    	 	27	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


PURCHASER
SIGNATURE PAGE TO CJJD SECURITIES PURCHASE AGREEMENT


 


IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.


 


Name
of Purchaser:CareRetail Holdings Limited


 


Signature
of Authorized Signatory of Purchaser:/s/ Dai Feng


 


Name
of Authorized Signatory:Dai Feng


 


Title
of Authorized Signatory:Director


 


Email
Address of Authorized Signatory:dai@carecapitalpartners.com


 


Facsimile
Number of Authorized Signatory:+852-2179 1900


 


Address
for Notice to Purchaser:


 


c/o
Suite 1608, One Exchange Square,





8
Connaught Place, Central, Hong Kong 


Attention:
Dai Feng


Fax:
+852-2179 1900


Email: 
dai@carecapitalpartners.com


 


With
copies to (which shall not constitute notice):


 


Legal@hillhousecap.com;
and


 


Skadden,
Arps, Slate, Meagher & Flom LLP

42/F, Edinburgh Tower, The Landmark

15 Queen’s Road Central

Hong Kong

Attention: Z. Julie Gao

Facsimile: +852.3910.4863

E-mail: julie.gao@skadden.com


 


Address
for Delivery of Securities to Purchaser (if not same as address for notice):


 


Subscription
Amount:US$10,648,000


 


Shares:4,840,000


 






    	 	28	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


Schedule
A



List of Subsidiaries


 


	1.	Renovation
    Investment (Hong Kong) Co., Ltd. (“Renovation”) is a Hong Kong company and is wholly-owned by the Company.
	 	 
	2.	Hangzhou
    Jiutong Medical Technology Co., Ltd. (“Jiutong Medical”) is a Chinese company and is wholly-owned by Renovation.
	 	 
	3.	Zhejiang
    Shouantang Pharmaceutical Technology Co., Ltd. (“Shouantang Technology”) is a Chinese company and is wholly-owned
    by Renovation.
	 	 
	4.	Zhejiang
    Jiuxin Investment Management Co., Ltd. (“Jiuxin Management”) is a Chinese company and is wholly-owned by Renovation.
	 	 
	5.	Hangzhou
    Jiuxin Qianhong Agriculture Development Co., Ltd. (“Qianhong Agriculture”) is a Chinese company and is wholly-owned
    by Jiuxin Management.
	 	 
	6.	Hangzhou
    Jiuzhou Grand Pharmacy Chain Co., Ltd. (“Jiuzhou Pharmacy”) is a Chinese company controlled by Jiuxin Management
    through contractual arrangements.
	 	 
	7.	Hangzhou
    Jiuzhou Clinic of Integrated Traditional and Western Medicine (General Partnership) is (“Jiuzhou Clinic”) a Chinese
    partnership controlled by Jiuxin Management through contractual arrangements.
	 	 
	8.	Hangzhou
    Jiuzhou Medical & Public Health Service Co., Ltd. (“Jiuzhou Service”) is a Chinese company controlled by Jiuxin
    Management through contractual arrangements.
	 	 
	9.	Zhejiang
    Jiuxin Medicine Co., Ltd. (“Jiuxin Medicine”) is a Chinese company and is wholly-owned by Jiuzhou Pharmacy.
	 	 
	10.	Shouantang
    Bio-technology Co., Ltd. (“Shouantang Bio”) is a Chinese company and is wholly-owned by Jiuzhou Pharmacy.
	 	 
	11.	Hangzhou
    Jiuyi Medical Technology Co. Ltd. (“Jiuyi Technology”) is a Chinese company and is wholly owned by Renovation.


 



    	 	S-A-1	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


Schedule
B



Capitalization


 





	Capitalization	 	 	 
	CJJD Capitalization as of December 31, 2016 prior to the Closing	 	 	 	 
	 	 	 	 	 
	Common Stock 	 	 	Shares	 
	Total Authorized Common Shares 	 	 	250,000,000	 
	Par Value       	 	$	0.001	 
	Total Issued and Outstanding Common Shares, not on a fully diluted basis	 	 	20,374,678	 
	 	 	 	 	 
	Options	 	 	 	 
	Total Issued and Outstanding Options	 	 	967,000	 
	 	 	 	 	 
	Warrants	 	 	 	 
	Total Issued and Outstanding Warrants	 	 	672,000	 
	 	 	 	 	 
	 On a fully diluted basis 	 	 	22,013,678	 





 






    	 	S-B-1	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


Schedule
C



Indebtedness


 


The
Company has credit facilities with Hangzhou United Bank (“HUB”), Bank of Hangzhou (“BOH”), Industrial
and Commercial Bank of China (“ICBC”) and Zhejiang Tailong Commercial Bank (“ZTCB”) that provided working
capital in the form of the following bank acceptance notes at September 30, 2016 and March 31, 2016:


 


	 	 	 	 	 	 	Origination	 	 	Maturity	 	 	September 30,	 	 	March 31,	 
	Beneficiary	 	 	Endorser	 	 	date	 	 	date	 	 	2016	 	 	2016	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	04/22/15	 	 	 	04/21/16	 	 	 	-	 	 	 	1,550,550	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	04/29/15	 	 	 	04/28/16	 	 	 	-	 	 	 	3,333,683	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	10/09/15	 	 	 	04/09/16	 	 	 	-	 	 	 	1,708,706	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	11/02/15	 	 	 	05/02/16	 	 	 	-	 	 	 	2,553,756	 
		Jiuzhou Pharmacy(2)	 	 	 	BOH	 	 	 	12/27/15	 	 	 	05/27/16	 	 	 	-	 	 	 	1,592,415	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	12/28/15	 	 	 	06/28/16	 	 	 	-	 	 	 	2,741,372	 
		Jiuzhou Pharmacy(2)	 	 	 	BOH	 	 	 	12/29/15	 	 	 	06/29/16	 	 	 	-	 	 	 	58,913	 
		Jiuzhou Pharmacy(3)	 	 	 	ICBC	 	 	 	02/03/16	 	 	 	08/03/16	 	 	 	-	 	 	 	1,307,114	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	03/07/16	 	 	 	09/07/16	 	 	 	-	 	 	 	2,749,125	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	04/05/16	 	 	 	10/05/16	 	 	 	1,280,317	 	 	 	-	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	05/06/16	 	 	 	11/06/16	 	 	 	1,601,737	 	 	 	-	 
		Jiuzhou Pharmacy(2)	 	 	 	BOH	 	 	 	06/06/16	 	 	 	12/06/16	 	 	 	2,128,394	 	 	 	-	 
		Jiuzhou Pharmacy(4)	 	 	 	ZTCB	 	 	 	06/24/16	 	 	 	12/24/16	 	 	 	599,680	 	 	 	-	 
		Jiuzhou Pharmacy(2)	 	 	 	BOH	 	 	 	06/27/16	 	 	 	12/27/16	 	 	 	749,600	 	 	 	-	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	06/29/16	 	 	 	12/29/16	 	 	 	1,247,334	 	 	 	-	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	08/05/16	 	 	 	02/05/17	 	 	 	1,462,141	 	 	 	-	 
		Jiuzhou Pharmacy(1)	 	 	 	HUB	 	 	 	08/29/16	 	 	 	02/28/17	 	 	 	2,604,963	 	 	 	-	 
			 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
		Total	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	11,674,166	 	 	$	17,595,634	 



 


	(1)	As
    of March 31, 2016, the Company had $14,696,105 (RMB94,779,950) of notes payable from HUB. The Company is required to hold
    restricted cash of $11,278,693 (RMB72,739,950) with HUB as collateral against these bank notes. As of September 30, 2016,
    the Company had $8,196,492 (RMB 54,672,441) of notes payable from HUB. The Company is required to hold restricted cash of
    $2,561,032 (RMB17,082,660) with HUB as collateral against these bank notes.
	(2)	As
    of March 31, 2016, the Company had $1,592,415 (RMB10,270,000) of notes payable from BOH. The land use right of the farmland
    in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required
    to hold restricted cash of $480,671 (RMB3,100,000) with BOH as collateral against these bank notes. As of September 30, 2016,
    the Company had $2,877,994 (RMB 19,196,865) of notes payable from BOH. The land use right of the farmland in Lin’An,
    Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted
    cash of $1,738,837 (RMB 11,598,432) with BOH as collateral against these bank notes.
	(3)	As
    of March 31, 2016, the Company had $1,307,114 (RMB8,430,000) of notes payable from ICBC, with restricted cash of $928,051
    (RMB5,985,300) held at the bank. As of September 30, 2016, the Company had no notes payable from ICBC.
	(4)	As
    of September 30, 2016, the Company had $599,680 (RMB4,000,000) of notes payable from ZTCB, with restricted cash of $299,840
    (RMB2,000,000) held at the bank.


 



    	 	S-C-1	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


As
of September 30, 2016, the Company had a credit line of approximately $14.02 million in the aggregate from HUB, BOH, ICBC
and ZTCB. By putting up the restricted cash of $4.30 million deposited in the banks, the total credit line was $18.32 million.
As of September 30, 2016, the Company had approximately $11.67 million of bank notes payable and approximately $6.65 million bank
credit line was still available for further borrowing. The bank notes are also secured by buildings owned by the Company’s
major shareholders, land use rights of Jiutong Medical, a shop of Jiuzhou Pharmacy, and guaranteed by Jiuxin Medical.


 


Amounts
payable to related parties are summarized as follows:


 


	 	 	September 30,

2016	 	 	March 31,

2016	 
	Due to cofounders (1):	 	$	576,818	 	 	$	576,818	 
	Due to a director and CEO (2):	 	 	1,694,972	 	 	 	1,622,957	 
	Total	 	$	2,271,790	 	 	$	2,199,775	 



 


	(1)	As
    of September 30, 2016 and March 31, 2016, amount due to cofounders represents contributions from the Owners to Jiuxin Management
    to enable Jiuxin Management to meet its approved PRC registered capital requirements.
	(2)	Due
    to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company
    to facilitate its payments of expenses in the United States.


 


As
of September 30, 2016 and March 31, 2016, notes payable totaling $4,943,875 and $5,302,881 were secured by the personal properties
of certain of the Company’s shareholders, respectively.


 





The
Company leases from Mr. Lei Liu a retail space which expires in September 2016. Rent expense amounted to $4,499 and $23,940 for
the three months ended September 30, 2016 and 2015, respectively.  Rent expense amounted to $9,092 and $48,510 for the
six months ended September 30, 2016 and 2015, respectively. The amounts were not paid to Mr. Liu as of September 30, 2016.


 






    	 	S-C-2	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


Schedule
D



Accountant


 


BDO
CHINA SHU LUN PAN Certified Public Accountants LLP


 






    	 	S-D-1	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


Exhibit
A-1


 

Joint Venture Operation Agreement


 



    	 	E-A-1-1	 



     


    

 


CONFIDENTIAL


EXECUTION VERSION



 


Exhibit
A-2


 


Joint Venture Charter



 


 


E-A-2-1